Zobrazeno 1 - 10
of 1 205
pro vyhledávání: '"63"'
Autor:
E. Ugartemendia, Gabriel Krygier, G. Sabini, I. Muse, A. Dellavalle, Cecilia Castillo, A. Viola
Publikováno v:
Journal of Clinical Oncology. 22:7568-7568
7568 Background: Uveal melanoma is the most common primary malignant intraocular tumor in adults (70%). They generally occur sporadically and familiy uveal melanoma only accounts for 0.6 % of patients. Methods: Data was collected from 63 patients ass
Publikováno v:
Journal of Clinical Oncology. 6:1584-1589
Sixty-three patients with T-cell lymphoma (TCL) were analyzed to correlate morphological and immunological features with clinical presentation, response to therapy, and survival. Clinical presentation was severe, with 59% of patients having stage IV
Autor:
Quchang Ouyang, Shusen Wang, Shiying Yu, Zhongsheng Tong, Zefei Jiang, Wei Li, Jianjun Zou, Xichun Hu, Y Liu, Fei Ma, Xiaoyu Zhu, Huiping Li, Jifeng Feng, Binghe Xu
Publikováno v:
Journal of Clinical Oncology. 37:2610-2619
PURPOSE Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine,
Autor:
Rachna T. Shroff, Milind Javle, Apurva Jain, Funda Meric-Bernstam, Ahmed Kaseb, Mitesh J. Borad, Thomas DeLeon, Reham Abdel-Wahab, Robin Kate Kelley, Ying Wang, Humaid O. Al-Shamsi, Daniel H. Ahn, Andrea Grace Bocobo, Keith A. Baggerly, Tanios Bekaii-Saab
Publikováno v:
JCO Precision Oncology. :1-12
Purpose FGFR genetic aberrations (GAs) occur in an estimated 10% to 16% of intrahepatic cholangiocarcinomas (CCAs). The natural history of CCA with FGFR GAs, the prognostic role of coexisting GAs, and the outcome with FGFR-targeted inhibitors are unk
Autor:
Brian Stwalley, Philip K Chan, Liwei Chen, Gurjyot K. Doshi, Nicholas J. Robert, S. Huo, Viviana Del Tejo, Daniel M. Geynisman
Publikováno v:
Journal of Clinical Oncology. 39:305-305
305 Background: Nivolumab plus ipilimumab (NIVO+IPI), a first-in-class combination immunotherapy, was approved by the US Food and Drug Administration in April 2018 for the treatment of intermediate- or poor-risk advanced renal cell carcinoma (RCC), a
Publikováno v:
Journal of Clinical Oncology. 39:270-270
270 Background: The standard of care for low-grade non‐muscle‐invasive bladder cancer (LG NMIBC) is transurethral resection of the bladder tumor, which can worsen health‐related quality of life (HRQOL). The “OPTimized Instillation of Mitomyci
Autor:
Dalia Littman, Fumiko Chino
Publikováno v:
Journal of Clinical Oncology. 39:e18662-e18662
e18662 Background: Smoking cessation after a cancer diagnosis improves cancer outcomes. Therefore, it is important for cancer centers to provide educational resources to encourage patients to quit smoking. The NIH recommends that patient reading mate
Publikováno v:
Journal of Clinical Oncology. 39:e17577-e17577
e17577 Background: Invasive extramammary Paget’s disease is most commonly in the vulva but can also occur in other genitalia as well as primary skin locations (face, scalp, neck, trunk, extremities). We aim to determine the clinicopathologic and pr
Autor:
Susan F. Slovin, Dana E. Rathkopf, Channing J. Paller, Michael J. Zelefsky, Daniel E. Spratt, Marisa A. Kollmeier, Robert B. Den, Howard I. Scher, Sean McBride, Han Xiao, Jason W.D. Hearn, Curtiland Deville, Wassim Abida
Publikováno v:
Journal of Clinical Oncology. 39:5012-5012
5012 Background: Standard of care in VHR PCa is radiation therapy (RT) with 18-36 months (mos) of androgen-deprivation therapy (ADT). With this regimen, chronic ADT toxicity is significant and biochemical recurrence (BCR) frequent. We sought to impro
Autor:
Fabian Lohaus, Christian Thomas, Tobias Hölscher, Manfred P. Wirth, Michael Baumann, Mechthild Krause, Jörg Kotzerke, Daniel Zips
Publikováno v:
Journal of Clinical Oncology. 39:115-115
115 Background: After curative primary therapy, a subset of patients with prostate cancer will have PSA-progression. Modern imaging methods may detect patients with oligometastastic disease at an early time point. Local ablative therapy has shown to